any validity to the thought that the FDA already has Glatopa 40 ready (it couldn't be that hard with 20 already approved) but can't go forward as they are very close with Mylan's first to file version and will issue a dual approval when they bless Mylan's?
Its interesting that this fairly short delay has already cost the system millions in lost savings. Anyone care to speculate the short term high once approval is obtained?
You need a little data to make such a claim. Teva sells the 40mg injector somewhere around $1200 a month less than the 20mg version. What numbers are you using that Sandoz will price the 40 mg version at?
If the FDA wants to save Millions a day they'll have to put out multiple entrants.